Showing results (551-560 of 706) with videos related to
Sort By:
Pageof 71
Mucosal Immunology|May 23, 2013
IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissueJ M Leung, M Davenport, M J Wolff, et al.Neurology|March 13, 2024
CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain InjuryGe Li, Jeffrey Iliff, Jane Shofer, et al.The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Congestive heart failure risk in patients with breast cancer treated with bevacizumabToni K Choueiri, Erica L Mayer, Youjin Je, et al.Archives of Environmental Contamination and Toxicology|March 8, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part III. Effluent toxicity testsF J Dwyer, D K Hardesty, C E Henke, et al.Circulation|November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery diseaseK Robinson, E L Mayer, D P Miller, et al.Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.The American Journal of Gastroenterology|April 24, 2001
The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset diseaseP N Akolkar, B Gulwani-Akolkar, X Y Lin, et al.Pageof 71